Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Black Friday Sale
    Black Friday Sale
    HomeNewsBusinessLupin gets tentative USFDA nod for generic Apixaban tablets

    Lupin gets tentative USFDA nod for generic Apixaban tablets

    Eliquis tablets 2.5 mg and 5 mg had annual sales of approximately $6,366 million in the US, Lupin added.

    PTI
    December 10, 2018 / 19:13 IST
    Lupin | Rakesh Jhunjhunwala increased stake in company to 1.53 percent in September quarter, from 1.47 percent in June quarter; LIC also raised stake to 3.71 percent from 2.7 percent and MFs to 12.58 percent from 11.94 percent. (Image: Reuters)
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Drug firm Lupin said it has received a tentative nod from the US health regulator to market its generic Apixaban tablets.

      The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Apixaban tablets in the strengths of 2.5 mg and 5 mg, Lupin said in a filing to BSE.

      The product is a generic version of Bristol-Myers Squibb Company's Eliquis tablets in the same strengths, it added.

      Eliquis tablets 2.5 mg and 5 mg had annual sales of approximately $6,366 million in the US, Lupin added.

      The tablets are used for reducing the risk of stroke and systemic embolism in non valvular atrial fibrillation, among other purposes.

      PTI
      first published: Dec 10, 2018 06:57 pm

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347